The Androgen Blind Spot: Why Your Midlife Body Still Feels Off — Even When Tests Come Back Normal
In this article
- Is this you?
- How androgen physiology shifts with age
- Why standard testing misses the picture
- What drives androgen decline — beyond ageing
- How we actually assess androgen status
- Real-world clinical presentations
- The ROOT Method applied to androgen decline
- Therapeutic approaches — hormonal and non-hormonal
- Frequently asked questions
There is a pattern I see with some regularity in clinic. A patient in their mid-forties or fifties arrives having done everything right. They exercise, eat well, manage their stress reasonably well. They have had blood tests. Testosterone came back "normal." Oestrogen within range for their age. Thyroid fine. And yet: persistent fatigue that does not resolve with rest, muscle that is harder to build and easier to lose, motivation that has flatlined, libido that has quietly disappeared, and a general sense that their body is no longer responding the way it used to.
The GP has run the numbers. The numbers are unremarkable. The patient is told this is normal ageing. Sometimes they are offered antidepressants. Sometimes they are referred to a psychologist. What they are rarely offered is a more sophisticated look at the androgen picture — not just the levels, but the metabolism, the binding proteins, the conversion pathways, and the stress hormones that compete with and suppress androgen function at the tissue level.
This is the androgen blind spot. It is not rare. And it is addressable.
Does this presentation resonate?
Suboptimal androgen function in midlife commonly presents as:
- Persistent fatigue that does not improve with adequate sleep — particularly flat morning energy
- Loss of muscle mass or difficulty maintaining muscle despite consistent exercise
- Reduced exercise capacity, slower recovery, or loss of competitive edge
- Low libido — in both women and men
- Mood flattening, loss of motivation, or mild depression that does not have an obvious situational cause
- Brain fog, poor concentration, or reduced mental sharpness compared to previous years — androgens directly support cognitive function via neurosteroid activity and mitochondrial support in neurons
- Increased central adiposity — fat accumulating around the abdomen despite no obvious dietary change
- In women: symptoms that have worsened significantly since perimenopause began, particularly fatigue and libido changes that oestrogen therapy alone has not resolved
- In men: gradual onset of the above symptoms across the forties with standard testosterone testing returning "within range"
These presentations often have an androgen component that standard assessment has not fully characterised. That is what a functional hormonal workup investigates.
How androgen physiology shifts with age — what is clinically relevant
Androgens are not exclusively male hormones. Testosterone, DHEA, DHEA-S, androstenedione, and dihydrotestosterone (DHT) are produced and active in both sexes. The differences are in quantity and in the tissue-level effects — but the fundamental biology is shared, and the age-related decline affects both men and women in ways that clinical practice consistently underestimates.
In women
Testosterone in women is produced by the ovaries, the adrenal glands, and peripheral tissues. The ovaries contribute approximately 25% of total testosterone production; the adrenal glands another 25%; and peripheral conversion of androgen precursors accounts for the remainder. As ovarian function declines in perimenopause, testosterone production from the ovaries drops. But the decline in testosterone can begin earlier and be more clinically significant than the standard narrative around female hormonal ageing suggests.
DHEA and DHEA-S — adrenal androgens that serve as precursors to both testosterone and oestrogen — begin declining from around age 25 in a process called adrenopause. By the mid-forties, DHEA-S levels may be 50-60% of what they were at peak. This matters because DHEA is the primary androgen precursor for peripheral testosterone production in women — and because it has independent metabolic and immune-modulatory effects that make its decline clinically significant beyond its role as a testosterone precursor.
The result is that many perimenopausal women are dealing with concurrent oestrogen fluctuation and androgen decline simultaneously — and the androgen component of their symptom picture is frequently not investigated or addressed. Oestrogen therapy may improve vasomotor symptoms and sleep, but it does nothing to address the fatigue, libido changes, and mood flattening that are driven by the androgen deficit. A comprehensive women's hormonal health assessment needs to include the full androgen picture alongside oestrogen and progesterone.
In men
Male testosterone declines at approximately 1-2% per year from around age 30 — a gradual process called andropause or late-onset hypogonadism. Unlike menopause, there is no discrete hormonal event that signals this transition. The decline is slow enough that men often adapt without recognising it until they compare their current function to ten years earlier.
What makes this clinically more complex than the simple decline narrative is the concurrent rise in SHBG (sex hormone-binding globulin) with age. SHBG binds testosterone in the bloodstream, rendering it biologically inactive. Total testosterone can remain within the laboratory reference range while free testosterone — the fraction actually available at the tissue level — declines significantly. A man with a total testosterone of 15 nmol/L and high SHBG may have less bioavailable testosterone than a man with a total of 12 nmol/L and low-normal SHBG. The total figure, which is what most standard panels report, does not tell you this.
Why standard testing misses the full picture
Standard testosterone testing typically measures total testosterone from a single morning serum sample. This is a starting point. It is not a complete androgen assessment, and for a significant proportion of midlife patients with suboptimal androgen symptoms, it is the reason the clinical picture gets missed.
The problems with single-point total testosterone testing:
It does not measure free or bioavailable testosterone
Total testosterone includes both bound and free fractions. Only free testosterone (roughly 2-3% of total) and loosely albumin-bound testosterone are biologically active at the tissue level. SHBG-bound testosterone is inactive. A total testosterone in the mid-normal range tells you almost nothing about tissue androgen exposure if SHBG is elevated — which it commonly is in midlife, with obesity, with insulin resistance, and with oestrogen-dominant states.
Clinical note: Free testosterone should be calculated or measured directly in any patient with symptomatic androgen insufficiency and a "normal" total testosterone. The Vermeulen equation uses total testosterone, albumin, and SHBG to calculate free testosterone — more accessible than direct measurement and sufficiently accurate for clinical purposes.
It ignores DHEA and DHEA-S
DHEA-S is the most abundant steroid hormone in the body and the primary precursor to both androgens and oestrogens in peripheral tissues. Its decline with age — adrenopause — is one of the most consistent findings in ageing physiology and one of the most consistently overlooked in standard hormone panels. A patient with low DHEA-S and normal total testosterone may have adequate circulating testosterone but a depleted androgen precursor pool that compromises resilience, immune function, and peripheral tissue androgen availability.
Clinical note: DHEA-S is inexpensive, stable in serum, and easily measured. It should be part of any comprehensive midlife hormonal workup. Reference ranges are wide — the clinically relevant question is where within the range the patient sits relative to optimal function for their age and symptom picture.
It ignores cortisol and the HPA axis
Cortisol and androgens share the same precursor — pregnenolone. Under chronic stress, the cortisol production pathway takes priority, diverting pregnenolone away from DHEA and testosterone synthesis. This "pregnenolone steal" is a direct biochemical mechanism by which chronic HPA axis activation suppresses androgen production. A patient whose total testosterone is borderline low and who is also carrying significant chronic stress may have adequate testosterone production capacity that is being actively suppressed by cortisol demand — a very different clinical picture from primary gonadal insufficiency, and one with a very different treatment approach.
Clinical note: A single serum cortisol is useless for assessing this. The diurnal cortisol pattern — four collection points across the day — is what reveals whether HPA axis dysregulation is competing with androgen synthesis. This is precisely what the salivary cortisol panel provides.
It does not assess androgen metabolism
Testosterone is metabolised into multiple downstream compounds with distinct physiological effects: DHT (via 5-alpha reductase — more potent androgenic activity, relevant for prostate, hair, and libido), oestradiol (via aromatase — in excess, contributes to oestrogen dominance in men and women), and several other metabolites. The rate and direction of these conversions are as clinically relevant as the testosterone level itself. A patient converting excess testosterone to oestradiol via elevated aromatase activity — common with visceral adiposity and insulin resistance — may have normal total testosterone but functional androgen insufficiency because the bioavailable fraction is being converted away.
Clinical note: Assessing aromatase activity requires either serum oestradiol alongside testosterone (basic), or ideally a comprehensive hormonal panel that includes the oestradiol:testosterone ratio and, where indicated, DHT levels. Elevated oestradiol in men with normal testosterone is a direct indicator of excess aromatase activity.
What drives androgen decline beyond ageing
Age is a backdrop, not an explanation. The rate and clinical significance of androgen decline varies enormously between individuals, and several modifiable factors directly accelerate it.
Chronic psychological stress and HPA overdrive
As described above, sustained cortisol demand directly suppresses androgen synthesis via pregnenolone competition. This is dose-dependent and cumulative. A person carrying two or three years of high-stress professional or personal demands will have measurably lower androgen output than the same person in a lower-stress period, independent of age. The fatigue, mood flattening, and reduced motivation that accompany androgen decline are often attributed to the stress itself — when they are, in part, the biochemical consequence of chronic stress on androgen physiology.
Clinical note: HPA axis rehabilitation — cortisol pattern normalisation, adaptogen support, sleep restoration — is often a prerequisite for meaningful androgen recovery in chronically stressed patients. Prescribing testosterone support into a dysregulated HPA environment produces inferior and less durable results.
Insulin resistance and visceral adiposity
Insulin resistance suppresses androgen production through multiple mechanisms: it reduces LH pulsatility (reducing gonadal testosterone stimulus), increases SHBG suppression in a paradoxical way that increases free oestrogen relative to free testosterone, and visceral fat tissue expresses high aromatase activity that converts androgens to oestrogens. The result is a compounding cycle: insulin resistance reduces androgens, low androgens reduce muscle mass and increase fat accumulation, which worsens insulin resistance. This cycle is extremely common in midlife and is one reason why metabolic health and hormonal health cannot be treated as separate clinical domains.
Clinical note: Fasting insulin, HOMA-IR, and waist circumference are as important as the hormone panel itself in assessing this picture. Metabolic intervention — dietary modification, resistance training, specific insulin-sensitising nutraceuticals — often produces meaningful androgen improvement without any direct hormonal therapy.
Sleep deprivation
The majority of testosterone release in both men and women occurs during sleep — specifically during deep slow-wave sleep and the early morning REM cycles. Sleep deprivation below six hours is associated with 10-15% reductions in testosterone in acute studies. Chronic poor sleep produces sustained androgen suppression. In men, the relationship is particularly direct: sleep apnoea is independently associated with low testosterone, and treating the apnoea reliably improves testosterone levels without any hormonal intervention.
Clinical note: Sleep quality is not optional in an androgen restoration protocol. A patient whose androgen function is not improving despite appropriate support almost always has an unaddressed sleep issue. A sleep history — including sleep apnoea screening — is part of every hormonal workup.
Nutritional insufficiency
Testosterone synthesis requires cholesterol as the starting substrate, zinc as a rate-limiting cofactor for testosterone-synthesising enzymes, vitamin D (which functions as a steroid hormone precursor and directly supports testicular and ovarian androgen production), magnesium (required for free testosterone — it competes with SHBG for testosterone binding, increasing the free fraction), and adequate dietary fat for steroidogenesis. Low-fat dietary protocols, zinc deficiency from poor diet or malabsorption, and vitamin D deficiency — extremely common in Australia's increasingly indoor population despite the climate — all directly impair androgen production.
Clinical note: Zinc, vitamin D, and magnesium should be assessed and corrected before any hormonal intervention is considered. In some patients, correcting these nutritional deficits alone produces clinically meaningful androgen improvement.
Oestrogen dominance and elevated SHBG
Elevated oestrogen — from excess aromatase activity, impaired oestrogen clearance, or exogenous sources — suppresses androgen production via negative feedback on the HPG axis. Elevated SHBG, which rises with oestrogen excess, liver stress, thyroid dysfunction, and ageing, binds and inactivates testosterone in circulation. Both mechanisms can produce symptomatic androgen insufficiency in the presence of normal total testosterone measurements — which is exactly why total testosterone alone is an insufficient assessment.
Clinical note: Addressing oestrogen dominance and SHBG elevation is frequently more effective than direct androgen support in women with this picture. Oestrogen clearance support (liver Phase II, gut microbiome normalisation), aromatase inhibition via dietary and nutraceutical means, and insulin sensitivity improvement all reduce SHBG and increase free testosterone without direct hormonal therapy.
Feeling consistently off despite normal test results?
A 20-minute discovery call can clarify whether a comprehensive androgen and adrenal assessment makes sense for your presentation. No referral required.
Book a free discovery callHow we actually assess androgen status
A meaningful androgen workup in midlife requires more than a morning total testosterone. Here is the panel I use and why each component matters.
AdrenoCortex Female Hormone Saliva Panel
The salivary hormone panel is the cornerstone of functional androgen assessment at this clinic. Saliva measures free, bioavailable hormone — not total bound hormone — which is the fraction that matters at the tissue level. The panel includes oestradiol, progesterone, testosterone, DHEA-S, and a four-point diurnal cortisol pattern. This combination answers the questions that a standard serum testosterone cannot:
- What is the free testosterone level — not just total?
- What is the oestradiol:testosterone ratio — is aromatase converting androgens to oestrogens?
- What is the DHEA-S level — is the adrenal androgen precursor pool depleted?
- What is the diurnal cortisol pattern — is HPA axis dysregulation actively suppressing androgen synthesis?
- What is the progesterone level — is pregnenolone steal a factor?
The cortisol pattern is particularly informative. A flattened curve, inverted pattern, or elevated nocturnal cortisol alongside low DHEA-S and low testosterone tells a coherent clinical story — chronic stress-driven androgen suppression — that a total testosterone of 12 nmol/L from a single morning blood draw does not.
Comprehensive Blood Panel
In addition to the salivary panel: serum total testosterone, calculated free testosterone (via Vermeulen equation using total T, albumin, and SHBG), SHBG, LH and FSH (to distinguish primary gonadal insufficiency from secondary/functional suppression), oestradiol, DHT where indicated, 25-OH vitamin D, serum zinc, red cell magnesium, fasting insulin and HOMA-IR, full thyroid panel (TSH, free T3, free T4, antibodies), and high-sensitivity CRP. These markers together contextualise the hormonal picture and identify the modifiable metabolic drivers.
Organic Acids Test (OAT)
Where fatigue, brain fog, and reduced exercise capacity are prominent alongside the androgen picture, the OAT adds the mitochondrial dimension. Androgen hormones support mitochondrial biogenesis — testosterone upregulates PGC-1α, the master regulator of mitochondrial synthesis. The relationship between androgen decline and mitochondrial dysfunction is bidirectional: low androgens reduce mitochondrial density; impaired mitochondrial function reduces the energy available for steroidogenesis. For patients where the androgen and the fatigue picture are both significant, the OAT provides the metabolic data that links them. This overlap between androgen decline and chronic fatigue is one of the most consistently missed connections in midlife health assessment.
Real-world clinical presentations
Case Presentation — Woman, 48
Presentation: Perimenopausal woman, 18 months of fatigue, complete loss of libido, increasing difficulty maintaining muscle despite consistent gym attendance, mood described as "flat rather than depressed." Had been offered an antidepressant by GP. Standard blood tests including oestradiol and total testosterone within reference range.
Salivary panel findings: Free testosterone low-normal; DHEA-S at the 15th percentile for age; oestradiol:testosterone ratio elevated, suggesting excess aromatase conversion; cortisol pattern — elevated morning cortisol with flat afternoon, consistent with early-stage HPA dysregulation; progesterone low-normal, consistent with anovulatory cycles.
Additional findings: Vitamin D 52 nmol/L (suboptimal), zinc deficient, fasting insulin elevated at 14 mU/L, HOMA-IR 2.8 — consistent with insulin resistance driving aromatase activity.
Clinical approach: HPA axis support via ashwagandha and phosphatidylserine; insulin sensitisation via dietary modification and berberine; vitamin D and zinc repletion; oestrogen clearance support to reduce aromatase substrate and improve free testosterone availability. Resistance training programme formalised. At 12 weeks: libido partially restored, fatigue significantly improved, mood normalised. No antidepressant required.
Case Presentation — Man, 52
Presentation: Progressive fatigue over three years, loss of gym motivation and physical performance, increased abdominal fat despite unchanged diet, low morning energy, reduced libido. GP had measured total testosterone at 13.2 nmol/L — reported as within the normal range (reference 8-29 nmol/L). No further investigation offered.
Salivary and blood panel findings: Free testosterone calculated at 180 pmol/L — below optimal range for age; SHBG elevated at 58 nmol/L; DHEA-S at 20th percentile; cortisol pattern — low morning cortisol with afternoon elevation, consistent with advanced HPA axis dysregulation; oestradiol 142 pmol/L — elevated for a male, consistent with aromatase excess; fasting insulin 18 mU/L, HOMA-IR 3.9; 25-OH vitamin D 44 nmol/L.
Clinical approach: Dietary intervention targeting insulin resistance (low glycaemic index, increased protein, removal of refined carbohydrates and alcohol); resistance training three times weekly; aromatase inhibition via DIM, zinc, and dietary intervention; vitamin D repletion to 120 nmol/L; HPA axis support; sleep assessment revealed habitual 5.5-hour nights — sleep extension protocol implemented. At 16 weeks: free testosterone recalculated at 260 pmol/L; oestradiol reduced to 98 pmol/L; HOMA-IR improved to 1.8; patient reported significant energy improvement and 4kg reduction in abdominal circumference.
The number in the reference range does not tell you whether a person is functioning optimally. It tells you they are not at the extreme end of a wide population distribution. For midlife patients with androgen-related symptoms, optimal and within-range are not the same thing.
The ROOT Method applied to androgen decline
The ROOT Method™: Applied to Midlife Androgen Decline
The ROOT Method works through four investigative layers. For androgen decline in midlife, each layer has specific clinical content:
- R — Root Cause Identification: Is the androgen decline primary (gonadal insufficiency — LH/FSH elevated with low testosterone), functional/secondary (HPA suppression, insulin resistance, aromatase excess, SHBG elevation), or nutritional (zinc, vitamin D, magnesium deficiency impairing steroidogenesis)? The mechanism determines the treatment. Addressing the cortisol-driven suppression pattern is the prerequisite — not the afterthought.
- O — Optimise Function: HPA axis rehabilitation to reduce cortisol competition for pregnenolone; insulin sensitisation to reduce aromatase activity and improve free testosterone; SHBG reduction via metabolic intervention; nutritional repletion of zinc, vitamin D, and magnesium; sleep quality optimisation; resistance exercise as a primary androgen stimulus.
- O — Ongoing Monitoring: Salivary hormone panel at baseline and 12 weeks to track free testosterone, DHEA-S, oestradiol:testosterone ratio, and cortisol pattern. Serum free testosterone, SHBG, and metabolic markers at the same intervals. Symptom tracking alongside objective data — because how a patient feels is the point, not just the numbers.
- T — Total Health Integration: Body composition, sleep architecture, stress physiology, dietary quality, insulin sensitivity, and toxic burden (environmental oestrogens, alcohol, plasticisers) — all addressed as drivers of the androgen picture, not separate health domains. The androgen system does not operate independently of the rest of the body's hormonal and metabolic environment.
Therapeutic approaches — hormonal and non-hormonal
Non-hormonal — addressing the modifiable drivers first
Resistance training is the most potent non-pharmacological androgen stimulus available. Compound movements — squats, deadlifts, rows, presses — produce acute testosterone and growth hormone responses and, with consistent practice, drive mitochondrial biogenesis and improve insulin sensitivity simultaneously. Two to three sessions per week of progressive resistance training is the non-negotiable foundation of any androgen restoration protocol.
Dietary intervention for androgen optimisation centres on three targets: reducing refined carbohydrate and sugar intake to improve insulin sensitivity and reduce aromatase activity; ensuring adequate dietary fat (including saturated fat from whole food sources) as cholesterol substrate for steroidogenesis; and increasing dietary zinc through red meat, shellfish (oysters in particular), and seeds. Alcohol reduction is clinically significant — alcohol directly inhibits testosterone synthesis in the testes and increases aromatase activity in the liver.
Zinc is arguably the most clinically important single nutrient for androgen function. It is a direct cofactor for testosterone-synthesising enzymes in the testes and ovaries, it inhibits aromatase activity, and it is required for LH receptor sensitivity. Zinc deficiency is common in the Australian adult population and is poorly captured by serum zinc alone (which reflects recent dietary intake rather than functional status). Zinc picolinate or zinc bisglycinate at 25-50mg elemental zinc daily is the standard clinical dose for repletion.
Vitamin D functions as a steroid hormone precursor and directly supports androgen synthesis in both gonads and adrenal tissue. Multiple studies have demonstrated that correcting vitamin D deficiency increases testosterone — a 2011 randomised controlled trial in Hormone and Metabolic Research found that 3,332 IU daily of vitamin D3 over 12 months produced significantly higher testosterone levels compared to placebo in vitamin D-deficient men. Target serum 25-OH vitamin D of 100-150 nmol/L for androgen optimisation — substantially above the standard "sufficient" threshold of 50 nmol/L.
Ashwagandha (Withania somnifera) has the strongest clinical evidence among adaptogens for androgen support. A 2019 RCT in Medicine found that ashwagandha at 600mg daily significantly increased testosterone, DHEA-S, and reduced cortisol compared to placebo over 8 weeks. The mechanism is via HPA axis modulation — reducing the cortisol competition for pregnenolone — rather than direct gonadal stimulation. This makes it particularly appropriate for the stress-driven androgen suppression pattern, which is the most common presentation in clinical practice.
DIM (diindolylmethane) reduces aromatase activity and shifts oestrogen metabolism toward less potent metabolites, reducing the oestrogen burden that suppresses androgen production and elevates SHBG. Most useful in patients where the oestradiol:testosterone ratio is elevated — which, in men with insulin resistance and visceral adiposity, and in perimenopausal women with functional oestrogen dominance, is a common finding.
Hormonal approaches — when and how
Direct hormonal intervention — testosterone therapy — has a place in clinical management but sits outside the prescribing scope of naturopathic practice in Australia and requires a medical prescriber. The naturopathic role is to ensure that everything modifiable has been addressed before that pathway is considered — and that the prescribing clinician has the full hormonal and metabolic picture rather than just a total testosterone result.
Where the comprehensive workup clearly demonstrates primary hypogonadism (elevated LH/FSH with low free testosterone) that has not responded to non-hormonal intervention, referral to an endocrinologist or GP experienced in hormone management is the appropriate next step. The functional medicine assessment provides the clinical context — the cortisol pattern, the metabolic picture, the aromatase and SHBG data — that makes any subsequent hormonal intervention more targeted and more likely to produce durable results.
Ready to properly investigate your androgen picture?
Initial consultation $197. In-clinic at Kealba, Melbourne, or via telehealth nationally. No referral required.
Book your free discovery callFrequently asked questions
Can women have low testosterone?
Yes — and it is more common and more clinically significant than most practitioners acknowledge. Testosterone in women supports libido, energy, muscle maintenance, mood, and cognitive function. Both ovarian and adrenal testosterone production decline with age, and the decline often accelerates in perimenopause. Women who have had oophorectomy (surgical removal of ovaries) experience a more abrupt and severe testosterone decline than those going through natural menopause. Female androgen insufficiency is real, measurable, and addressable — but it requires appropriate testing, including free testosterone and DHEA-S, not just a standard oestrogen panel.
Why does total testosterone come back normal when I have all the symptoms of low testosterone?
Several reasons. First, total testosterone includes both bound (inactive) and free (active) fractions — if SHBG is elevated, the free fraction can be low even when total is normal. Second, reference ranges are wide and population-based — being "within range" does not mean optimal function for your age and physiology. Third, total testosterone does not capture DHEA-S (adrenal androgen precursor), the oestradiol:testosterone conversion ratio (aromatase activity), or the HPA axis cortisol pattern that is actively suppressing production. A comprehensive assessment requires free testosterone, SHBG, DHEA-S, oestradiol, and a diurnal cortisol profile.
What is DHEA and why does it matter?
DHEA (dehydroepiandrosterone) is an adrenal hormone and the most abundant steroid in the body. It is the primary precursor to both testosterone and oestrogen in peripheral tissues, and it has independent effects on immune function, energy metabolism, mood, and stress resilience. DHEA and its sulphated form DHEA-S decline progressively from around age 25 — a process called adrenopause — and by the mid-forties levels may be 40-60% of peak values. Low DHEA-S is associated with fatigue, reduced stress tolerance, impaired immune function, and reduced androgen availability. It is a clinically important marker that is frequently absent from standard hormonal panels.
Does stress lower testosterone?
Yes — directly and measurably. Cortisol and androgens are produced from the same precursor (pregnenolone). Under chronic stress, cortisol production takes priority, reducing the substrate available for DHEA and testosterone synthesis. This is called pregnenolone steal. Additionally, elevated cortisol directly suppresses LH pulsatility from the pituitary, reducing the gonadal stimulus for testosterone production. Chronic HPA axis activation is one of the most common and most treatable causes of functional androgen insufficiency in midlife — and one that a single testosterone blood test will not identify without also measuring the cortisol pattern.
What is the best test for androgen assessment in midlife?
A salivary hormone panel measuring free testosterone, DHEA-S, oestradiol, progesterone, and four-point diurnal cortisol gives the most complete functional picture for midlife androgen assessment. It captures free bioavailable hormone rather than total bound hormone, maps the HPA axis cortisol pattern that suppresses androgen synthesis, and gives the oestradiol:testosterone ratio that indicates aromatase activity. This should be combined with a serum panel including total testosterone, SHBG, calculated free testosterone, LH, FSH, vitamin D, zinc, and metabolic markers (fasting insulin, HOMA-IR).
Can you improve testosterone naturally without hormone therapy?
Yes — in many cases substantially. Resistance training, sleep optimisation, insulin sensitisation through dietary modification, zinc and vitamin D repletion, HPA axis rehabilitation, aromatase inhibition through DIM and dietary intervention, and alcohol reduction all produce measurable improvements in free testosterone. For patients whose androgen decline is functional — driven by stress, metabolic dysfunction, or nutritional insufficiency — non-hormonal intervention is often sufficient and more durable than direct hormonal therapy, because it addresses the drivers rather than supplementing around them.
Do I need a referral for a naturopathic hormonal assessment?
No referral is required at Vital Health and Natural Medicine. Initial consultations are $197 and available in-clinic at Kealba, Melbourne, or via telehealth nationally. For patients unsure whether a comprehensive androgen assessment is appropriate for their presentation, a free 20-minute discovery call is the right starting point.
Related reading: Women's hormonal health at Vital Health | Chronic fatigue and hormonal drivers | Cognitive health and hormonal function | Adrenal Cortex Hormone Saliva Panel | Organic Acids Test | Book a discovery call
Disclaimer: This article is for educational purposes and does not constitute medical advice. Hormone assessment and treatment should be undertaken with a qualified health professional. This content is prepared by Domenic Pisanelli, naturopath and functional medicine practitioner (ATMS registered), at Vital Health and Natural Medicine, 195A Sunshine Ave, Kealba VIC 3021. Phone: 03 9382 9790.
